clinical trial · NCT05308264
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Low Risk Myelodysplastic SyndromesR906289 Monosodium (R289 Na)
brief summary
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
started
Sep 12, 2022
primary completion
Aug 1, 2026
completion
Dec 1, 2026
last updated
Oct 21, 2025
detailed description
An open-label, Phase 1b study of R289, an IRAK 1/4 Inhibitor, to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed/refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), luspatercept, or hypomethylating agents (HMAs) for MDS.
official title
An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol